Background {#Sec1}
==========

Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport proteins (SGLT2) and it is often used to treat patients with type 2 diabetes mellitus (T2DM) \[[@CR1]\]. This drug works by blocking glucose absorption in the kidneys, thereby eliminating glucose through urine \[[@CR2], [@CR3]\]. The mechanism of action of this drug renders it safe to be used and it results with less hypoglycemic events compared to other oral hypoglycemic agents (OHAs) such as sulfonyl urea, and even insulin. Canagliflozin can be administered alone (monotherapy), or in combination with other OHAs such as metformin, pioglitazone, sulfonylurea, and even insulin depending on the treatment regimen being followed. Several studies have compared canagliflozin with other OHAs showing the former to have more beneficial effects in these patients who were treated for T2DM \[[@CR4]\].

Similar to other drugs, canagliflozin also has adverse drug effects (AEs). A systematic review and meta-analysis carried out by Yang et al confirmed common AEs such as genital tract infections, which are associated with the use of canagliflozin when it was compared to other OHAs \[[@CR5]\]. Another meta-analysis showed genital mycotic infections and pollakiuria to be associated with the use of canagliflozin in comparison with another OHA \[[@CR6]\]. However, the AEs associated with 100 mg versus 300 mg canagliflozin respectively, have seldom been studied. Therefore, the main objective of this analysis was to systematically compare the AEs which were associated with 100 mg versus 300 mg canagliflozin respectively, using a large number of randomized patients with T2DM which were obtained from published trials.

Methods {#Sec2}
=======

Data sources and search strategy {#Sec3}
--------------------------------

PubMed/Medline, EMBASE and the Cochrane databases were searched (from June to August 2016) for relevant English publications of randomized controlled trials (RCTs) comparing 100 mg with 300 mg canagliflozin in patients who were treated for T2DM. During this search process, the following terms were used:Canagliflozin and diabetes mellitus;Canagliflozin and type 2 diabetes mellitus;Sodium glucose co-transporter 2-inhibitor and diabetes mellitus;Canagliflozin 100 mg versus canagliflozin 300 mg;Canagliflozin and T2DM;SGLT2 and type 2 diabetes mellitus.

To further ensure that we did not miss any trial, the term 'canagliflozin' alone was also used, and all the trials obtained were cross checked once.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies were included if:They were RCTs comparing 100 mg with 300 mg canagliflozin in patients who were treated for T2DM.They reported adverse drug events among their safety outcomes.They were published in English language.

Studies were excluded if:They were non-RCTs (meta-analyses, case studies or observational studies).They did not compare 100 mg with 300 mg canagliflozin in patients who were treated for T2DM.They compared 100 mg with 300 mg canagliflozin in patients who were treated for T2DM, but these trials only compared outcomes which were related to efficacy without comparing outcomes which were related to adverse drug events.They involved unpublished data.

Endpoints, definitions and follow up periods {#Sec5}
--------------------------------------------

Adverse drug events which were reported in these trials (Table [1](#Tab1){ref-type="table"}) were considered as the clinical endpoints in this analysis. The following AEs were reported:Table 1Reported adverse outcomesTrialsAdverse events reportedFollow up (weeks)Blonde 2016 \[[@CR9]\]Any AEs, AEs leading to drug discontinuation, hypoglycemia episodes104Forst 2014 \[[@CR10]\]Any AEs, AEs leading to discontinuation, serious AEs, deaths, UTI52Neal 2015 \[[@CR11]\]Any AEs, AEs causing discontinuation, serious AEs, deaths, UTI, documented and severe hypoglycemia18Gonzalez 2013 \[[@CR12]\]Any AEs, AEs leading to discontinuation, serious AEs, UTI, postural dizziness52Inagaki 2013 \[[@CR13]\]Hypoglycemia12Inagaki 2014Discontinuation due to AEs52Stenlof 2013 \[[@CR15]\]Any AEs, AEs leading to discontinuation, serious AEs, death, UTI, postural dizziness26Wilding 2013 \[[@CR16]\]Any AEs, AEs leading to discontinuation, serious AEs, deaths, UTI, hypoglycemia52Yale 2013 \[[@CR17]\]Any AEs, AEs leading to discontinuation, serious AEs, deaths, UTI, postural dizziness26Rosenstock 2012 \[[@CR18]\]Any AEs, serious AEs, discontinuation due to AEs, UTI, hypoglycemia12*Abbreviations*: *AEs* adverse events, *UTI* urinary tract infections Any adverse events;Adverse events requiring drug discontinuation;Serious adverse events;Deaths;Urinary tract infections (UTIs);Postural dizziness;Hypoglycemia.

In this analysis, 'any adverse event' was reported in eight trials whereas adverse events leading to drug discontinuation were reported in nine trials. Seven trials reported serious adverse events and UTIs respectively. Death and hypoglycemia were reported in five trials each whereas postural dizziness was reported in three trials. One trial had a follow up period of 104 weeks, four trials had a follow up period of 52 weeks, and five other trials had a follow up period of less than or equal to 26 weeks (Table [1](#Tab1){ref-type="table"}).

In this analysis, serious adverse events were defined as adverse events that were severe enough and required the assistance of another individual/medical staff or adverse events that resulted in seizures or/and loss of consciousness shortly following their occurrence.

UTIs were defined as infections which were related to the genitals, whether asymptomatic or with symptoms such as frequent urination, painful urination, any urethral discharge, or foul smelling of urinary organs.

Hypoglycemia was defined as a decrease in blood glucose level below 3.9 mmol/L (70 mg/dL).

Data extraction and Quality assessment {#Sec6}
--------------------------------------

Two authors (PKB and GJ) carefully assessed all the trials which were selected for this analysis. Information concerning the type of study which was reported, the total number of patients who were treated by 100 and 300 mg canagliflozin respectively, data concerning the baseline features, the reported adverse drug events and the corresponding follow up periods reported in the trials, were carefully extracted by these two authors. Any confusion or disagreement that followed was resolved by the third author (FH).

Bias risks which were observed in those eligible trials were assessed with reference to the components recommended by the Cochrane Collaboration \[[@CR7]\] as shown in Table [2](#Tab2){ref-type="table"}. The six components recommended by the Cochrane Handbook were assessed and a score of 0, 1 and 2 was given to a high, unclear and low risk of bias respectively. A minimum total score of 0 and a maximum total score of 12 was possible.Table 2Quality assessment of the trials according to the Cochrane CollaborationTrialsABCDEFTotal score (n/12)Blonde 2016 \[[@CR9]\]22122110Forst 2014 \[[@CR10]\]2211219Neal 2015 \[[@CR11]\]21222110Gonzalez 2013 \[[@CR12]\]22122110Inagaki 2013 \[[@CR13]\]2211219Inagaki 20142111218Stenlof 2013 \[[@CR15]\]21222110Wilding 2013 \[[@CR16]\]21222110Yale 2013 \[[@CR17]\]21222110Rosenstock 2012 \[[@CR18]\]21222110A: sequence generation; B: concealment of allocation; C: Blinding of patients; D: Blinding of caregivers; E: Blinding of outcome assessors; F: Follow-up and intention-to treat analysis

Statistical analysis {#Sec7}
--------------------

The Preferred Reporting Items for Systematic Reviews and Meta*-*Analyses (PRISMA) guideline was followed for this analysis which involved only randomized trials \[[@CR8]\]. Heterogeneity across the studies was calculated/assessed using the Cochrane Q-statistic test (*P* ≤ 0.05 was considered statistically significant) and the I^2^-statistic test (lower I^2^ value indicated a lower heterogeneity and higher I^2^ value represented an increasing heterogeneity).

In addition, a fixed (*I* ^2^ \< 50%) or a random (*I* ^2^ \> 50%) effects model was used based on the I^2^ values obtained.

Publication bias could visually be estimated by assessing funnel plots.

We calculated odds ratios (OR) with 95% confidence intervals (CIs) and the analyses were carried out by the RevMan 5 **·** 3 software.

Ethics {#Sec8}
------

Ethical approval was not required for this study.

Results {#Sec9}
=======

Search results {#Sec10}
--------------

Six hundred and forty-five (645) articles were obtained from the searched databases. In the beginning, 529 articles were eliminated since they did not match with the scope of this analysis. One hundred and sixteen (116) full-text articles were assessed for eligibility. Further eliminations occurred based on the following criteria:Meta-analyses (7);Pooled analyses (8);They were different studies which involved the same trials (28);Duplicates (63).

Finally, 10 trials \[[@CR9]--[@CR18]\] were considered eligible for this analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram for the study selection

General features of the included studies {#Sec11}
----------------------------------------

A total number of 5394 patients were included (2604 patients were treated by 100 mg canagliflozin and 2790 patients were treated by 300 mg canagliflozin) as shown in Table [3](#Tab3){ref-type="table"}.Table 3General features of the trials which were included in this analysisTrialsType of studyPatients enrollment periodNo of patients using 100 mg CANA (n)No of patients using 300 mg CANA (n)Trial numberBlonde 2016 \[[@CR9]\]RCT2009-2013724721NCT00968812 + NCT01106651Forst 2014 \[[@CR10]\]RCT2010-2012113114NCT01106690Neal 2015 \[[@CR11]\]RCT2009-2011692690NCT01032629Gonzalez 2013 \[[@CR12]\]RCT2010-2012368367NCT01106677Inagaki 2013 \[[@CR13]\]RCT2009-20107475NCT01022112Inagaki 2014 \[[@CR14]\]RCT2011-2012127253NCT01387737Stenlof 2013 \[[@CR15]\]RCT2010-2012195197NCT01081834Wilding 2013 \[[@CR16]\]RCT2010-2012157156NCT01106625Yale 2013 \[[@CR17]\]RCT-9089-Rosenstock 2012 \[[@CR18]\]RCT2008--200964128NCT00642278Total no26042790*Abbreviations*: *RCT* randomized controlled trials, *CANA* canagliflozin

The patients' enrollment periods, the trial registration number, and the total number of patients treated with 100 and 300 mg canagliflozin respectively, have all been listed in Table [3](#Tab3){ref-type="table"}.

According to Table [3](#Tab3){ref-type="table"}, the enrollment periods of the patients varied between years 2008 and 2012.

Baseline characteristics {#Sec12}
------------------------

The baseline features have been listed in Table [4](#Tab4){ref-type="table"}.Table 4Baseline features of the participantsTrialsMean age (y)Males (%)HbA1c (%)Duration (y)BMI (kg/m^2^)100/300 mg100/300 mg100/300 mg100/300 mg100/300 mgBlonde 2016 \[[@CR9]\]56.4/55.852.2/49.77.8/7.86.5/6.731.0/31.2Forst 2014 \[[@CR10]\]56.7/57.068.1/55.38.0/7.910.5/11.032.3/32.8Neal 2015 \[[@CR11]\]62.0/63.067.0/65.08.3/8.316.4/16.333.0/33.3Gonzalez 2013 \[[@CR12]\]55.5/55.347.3/45.07.9/7.96.7/7.132.4/31.4Inagaki 2013 \[[@CR13]\]57.7/57.170.3/73.38.05/8.17-25.6/25.9Stenlof 2013 \[[@CR15]\]55.1/55.341.5/45.28.1/8.04.5/4.331.3/31.7Wilding 2013 \[[@CR16]\]57.4/56.148.4/55.88.1/8.19.0/9.433.3/33.2Yale 2013 \[[@CR17]\]69.5/67.964.4/53.97.9/8.015.6/17.032.4/33.4Rosenstock 2012 \[[@CR18]\]51.7/52.356.0/56.07.8/7.76.1/5.931.7/31.6*Abbreviations*: *y* year, *HbA1c* glycosylated hemoglobin, *BMI* body mass index, Duration referred to duration of type 2 diabetes mellitus100 and 300 mg were referred to canagliflozin dosage

According to Table [4](#Tab4){ref-type="table"}, the participants had a mean age ranging from 51.7 to 69.5 years. Several studies reported a larger number of male patients compared to female patients. Glycosylated hemoglobin (HbA1c) ranged between 7.8 and 8.3%. Studies Neal \[[@CR11]\] and Yale \[[@CR17]\] involved patients with the longest duration period of T2DM as shown in Table [4](#Tab4){ref-type="table"}.

Anti-diabetic drugs which were used by the patients were not same in all the trials. A few trials involved participants who used only canagliflozin monotherapy, whereas other trials involved participants who used canagliflozin in combination with either metformin, sulfonylurea, thiazolidinediones, or insulin as shown in Table [5](#Tab5){ref-type="table"}.Table 5Other anti-diabetic drugs used by the patients apart from canagliflozinTrialsOther anti-diabetic drugs usedBlonde 2016 \[[@CR9]\]MetforminForst 2014 \[[@CR10]\]Metformin and pioglitazoneNeal 2015 \[[@CR11]\]Metformin, sulfonyl urea and insulinGonzalez 2013 \[[@CR12]\]MetforminInagaki 2013 \[[@CR13]\]Only canagliflozin monotherapyInagaki 2014Only canagliflozin monotherapyStenlof 2013 \[[@CR15]\]Only canagliflozin monotherapyWilding 2013 \[[@CR16]\]Metformin and sulfonyl ureaYale 2013 \[[@CR17]\]Metformin, sulfonylurea, thiazolidinediones, or insulinRosenstock 2012 \[[@CR18]\]Metformin

Adverse drug events analyzed {#Sec13}
----------------------------

The main results of this analysis were summarized in Table [6](#Tab6){ref-type="table"}.Table 6Results of this analysisOutcomes reportedNo of studies involved (n)OR with 95% CIP valuesI^2^ (%)Drug discontinuation91.35 \[1.06--1.72\]0.0131Serious AEs71.01 \[0.79--1.29\]0.930Deaths51.13 \[0.43--2.94\]0.800UTIs70.93 \[0.70--1.23\]0.610P. dizziness31.51 \[0.42--5.37\]0.530Hypoglycemia50.96 \[0.81--1.13\]0.600Any AEs81.04 \[0.85--1.28\]0.7252*Abbreviations*: *AEs* adverse events, *UTIs* urinary tract infections, *P. dizziness* postural dizziness, *OR* odds ratios, *CI* confidence intervals

The current results showed that, during a follow up period ranging from 12 to 104 weeks, serious adverse events were not significantly higher in patients treated by 300 mg canagliflozin with OR: 1.01, 95% CI: 0.79--1.29; *P* = 0.93. Also, a similar rate of death has been observed in patients treated by either 100 or 300 mg canagliflozin with OR: 1.13, 95% CI: 0.43--2.94; *P* = 0.80. UTIs, postural dizziness and hypoglycemia were also similarly manifested with OR: 0.93, 95% CI: 0.70--1.23; *P* = 0.61, OR: 1.51, 95% CI: 0.42--5.37; *P* = 0.53 and OR: 0.96, 95% CI: 0.81--1.13; *P* = 0.60 respectively. However, drug discontinuation due to adverse events significantly favored 100 mg canagliflozin with OR: 1.35, 95% CI: 1.06--1.72; *P* = 0.01. These results have been illustrated in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Adverse drug events associated with 100 and 300 mg canagliflozin (mean follow-up ranging from 12 to 104 weeks)

Even if a moderate level of heterogeneity has been observed when analyzing 'any type of adverse event', no significant difference in events were observed whether with 100 or 300 mg canagliflozin with OR: 1.04, 95% CI: 0.85--1.28; *P* = 0.72. This result which was analyzed by a random effects model, has been represented in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Any adverse drug events associated with 100 and 300 mg canagliflozin (mean follow-up ranging from 12 to 104 weeks)

Because this main analysis involved a combination of trials with different follow-up periods, new analyses were further carried out with trials involving similar follow-up periods.

Four trials had a follow-up period of 52 weeks. When these four trials were analyzed separately from the main result, no significant difference was observed in serious adverse drug events and UTIs with OR: 0.90, 95% CI: 0.53--1.53; *P* = 0.69 and OR: 0.82, 95% CI: 0.53--1.27; *P* = 0.38 respectively. Drug discontinuation due to adverse events was also not significantly different with OR:0.92, 95% CI: 0.58--1.47; *P* = 0.73 as shown in Fig. [4](#Fig4){ref-type="fig"}. Any adverse event was also similarly manifested with OR: 1.01, 95% CI: 0.59--1.75; *P* = 0.96 (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Adverse drug events associated with 100 and 300 mg canagliflozin (mean follow-up of 52 weeks) Fig. 5Any adverse drug events associated with 100 and 300 mg canagliflozin (mean follow-up of 52 weeks)

When a follow-up period of 26 weeks was considered, any adverse event, drug discontinuation, UTIs and postural dizziness were still not significantly different with OR: 0.90, 95% CI: 0.64--1.28; *P* = 0.57, OR: 0.60, 95% CI: 0.21--1.67; *P* = 0.33, OR: 0.89, 95% CI: 0.45--1.74; *P* = 0.72 and OR: 2.02, 95% CI: 0.37--11.12; *P* = 0.42 respectively as shown in Fig. [6](#Fig6){ref-type="fig"}.Fig. 6Adverse drug events associated with 100 and 300 mg canagliflozin (mean follow-up of 26 weeks)

In addition, hypoglycemia was assessed during a follow-up period of 12 weeks. However, no significant difference was observed with OR: 0.69, 95% CI: 0.13--3.64; *P* = 0.66 (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Hypoglycemia associated with 100 and 300 mg canagliflozin (mean follow-up of 12 weeks)

Publication bias {#Sec14}
----------------

After visually assessing the funnel plots, a low evidence of publication bias was observed across the trials involving several subgroups which assessed the adverse events associated with 100 mg versus 300 mg canagliflozin. The funnel plots representing publication bias have been illustrated in Figs. [8](#Fig8){ref-type="fig"} and [9](#Fig9){ref-type="fig"}.Fig. 8Funnel plot representing publication bias Fig. 9Funnel plot representing publication bias

Discussion {#Sec15}
==========

The current results showed no statistically significant differences in adverse drug events observed with 100 mg versus 300 mg canagliflozin in patients who were treated for T2DM. However, 300 mg dosage resulted in a significantly higher drug discontinuation only when a mean range of follow-up period (12 to 104 weeks) was considered but no significant difference in drug discontinuation was observed when trials with similar follow-up periods were compared.

Canagliflozin, which is a sodium-glucose transporter (SGLT-2) inhibitor, works by preventing the reabsorption of at least 90% of renal glucose, allowing the latter to be excreted in urine \[[@CR2]\]. Risk of hypoglycemia is also minimal as compared to other anti-diabetic medications. This current result showed that neither 100 nor 300 mg canagliflozin caused any significant increase in hypoglycemia among those patients who were treated for T2DM. Canagliflozin's mechanism of action also allows it to lower blood pressure in those patients with hypertension. In addition, canagliflozin also reduces postprandial glucose and insulin by delaying glucose absorption in the intestine \[[@CR19]\]. In addition to the result of this analysis, no significant difference observed between 100 mg versus 300 mg canagliflozin could represent a potential benefit for similar patients in the future.

The pooled analysis of clinical studies comparing the efficacy and safety of canagliflozin in older patients suffering from T2DM showed canagliflozin to maintain a good glycemic control, to result in weight reduction, to improve blood pressure and it was well tolerated \[[@CR20]\]. Another study using data pooled from four placebo-controlled phase 3 trials and two placebo-controlled sub-studies of a population of patients with inadequately controlled T2DM showed both dosages of canagliflozin (100 and 300 mg) to be well tolerated in Asians and in Black/African American \[[@CR21]\]. Furthermore, Bode et al also showed canagliflozin to be well tolerated in patients with T2DM aged between 55 and 80 years over a follow up period of 2 years \[[@CR22]\]. In addition of improving HbA1c, serious adverse events were not highly visible in patients who were treated with either 100 or 300 mg canagliflozin. A clinical review further discussed the safety of canagliflozin \[[@CR23]\].

Nevertheless, the pooled analysis by Bailey et al involving two clinical trials showed that during a follow up period of 1 year, canagliflozin 100 mg was associated with a comparable attainment of composite quality endpoint whereas 300 mg canagliflozin was associated with superior composite quality endpoint attainment \[[@CR24]\].

Despite so many benefits of canagliflozin, a recent study evaluating the safety of canagliflozin showed that the main adverse effect which was likely to be seen was a small increase in UTIs and fungal infections \[[@CR25]\]. Scientific research has also shown the association of canagliflozin with an increase in vaginal colonization with candida species and it was also associated with vulvovaginal adverse effects in women with T2DM \[[@CR26]\]. However, even if increased UTIs were observed with canagliflozin when compared to other OHAs, this current analysis showed that when two different dosages of the same drug were compared with each other, no significant difference was observed in UTIs. In addition, canagliflozin was also demonstrated to have potential adverse outcomes related to bones, thereby increasing the risk of fracture \[[@CR27], [@CR28]\].

Even if canagliflozin is associated with a small percentage of adverse drug events in these patients with T2DM, this current analysis showed that compared to a 100 mg dosage, a 300 mg dosage of canagliflozin was not associated with significantly higher adverse effects in these patients treated for T2DM, implying that both dosages are well tolerated in these patients \[[@CR29]\].

It should be noted that canagliflozin in combination with other anti-diabetic drugs such as insulin, might improve glycemic control and reduce body weight in these patients with T2DM, as shown in the study published by Inagaki et al \[[@CR30]\].

Novelty {#Sec16}
-------

This study is new in the way that, it is among the first meta-analyses comparing the adverse drug events associated with 100 mg versus 300 mg canagliflozin in patients treated for T2DM. Several studies have previously compared other OHAs with canagliflozin, however, their main focus was not based on the adverse drug events which were associated with 100 mg versus 300 mg canagliflozin. Another novelty could be the fact that this analysis involved a high number of randomized patients which should be expected to provide robust results. Moreover, physicians from the department of endocrinology, and patients who are treated for T2DM might be very much concerned about the different dosages and adverse events associated with canagliflozin. Therefore, this hypothesis, hopefully, might be useful to a certain extent.

Limitations {#Sec17}
-----------

This analysis also has several limitations. First of all, due to a small population size when compared to other published meta-analyses outside the scope of this research, the current results might have been affected. Moreover, all the eligible trials which were used in this analysis did not report the same follow up periods which could have also affected the results. However, this limitation was partly solved when trials with similar follow up periods were compared. Moreover, to compare safety outcomes, randomized trials might not be the most recommended sources of evidence in comparison to observational studies and their subtypes. Therefore, this might also represent another limitation of this analysis. Another main limitation could be the fact that all the trials did not involve only patients who were treated with canagliflozin monotherapy. Majority of the patients were also treated by metformin and/or other anti-diabetic medications. It should be noted that this could have had a high impact on the results obtained.

Conclusion {#Sec18}
==========

300 mg canagliflozin was not associated with significantly higher adverse events compared to 100 mg canagliflozin in those patients who were treated for T2DM. However, because this result was partly affected by other anti-diabetic medications which were included in the treatment regimen, further studies based on patients who were treated strictly on canagliflozin monotherapy should be recommended to completely solve this issue.
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